Lazerhead Lifesciences Private Limited

Lazerhead Lifesciences Private Limited, established on August 27, 2014, is a private pharmaceutical company headquartered in Jadcherla Mandal, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U24232TG2014PTC095428. As of the latest available data, Lazerhead Lifesciences has an authorized capital of ₹0.10 million and a paid-up capital of ₹0.10 million. The company is unlisted and operates in the pharmaceutical manufacturing sector, focusing on the production of finished pharmaceutical formulations.

The company's ownership structure is predominantly held by promoters, accounting for 92.83% of the shares, with the public holding 4.10% and others 3.07%. Lazerhead Lifesciences has experienced significant growth in revenue, with a 141.44% increase in the financial year ending March 31, 2023. However, profitability declined by 10.2%, and net worth decreased by 37.93% during the same period. The company's product portfolio is highly concentrated, with its top five products accounting for 100% of its export value. These products include Immunoglobulin and Theophylline, which are exported to various international markets.

Lazerhead Lifesciences operates two state-of-the-art manufacturing facilities in India. The first facility, located in the Green Industrial Park, Jadcherla, Telangana, covers a land area of 444,300 square feet, with an upcoming built-up area of over 200,000 square feet. This plant specializes in the production of cytotoxic oral solid dosages, sterile injectables, biopharmaceutical APIs, and sterile injectables in lyophilized vials and pre-filled syringes. The second facility, formerly known as MacMohan Pharma Ltd, is situated in Jeedimetla Industrial Area, Hyderabad, Telangana, and spans 43,500 square feet of land with a constructed area of 30,000 square feet. This plant focuses on the manufacturing of cytotoxic oral solid dosages and sterile injectable formulations.

Both facilities are equipped with advanced technology and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical products. The manufacturing units are designed to meet international standards, catering to both domestic and export markets. Lazerhead Lifesciences emphasizes a quality-driven culture, prioritizing the safety, efficacy, and reliability of its products.

Lazerhead Lifesciences is led by a team of experienced professionals committed to the company's growth and success. The key executives include:

• Yelamanchi Padma Rao: Director since August 27, 2014.

• Ruchika Rao Yelamanchi: Director since May 22, 2017.

The leadership team is dedicated to advancing health through science, innovation, and integrity, aligning with the company's mission to deliver safe, effective, and reliable pharmaceutical products.

Lazerhead Lifesciences has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its manufacturing facilities from the U.S. Food and Drug Administration (FDA), enabling it to export products to the U.S. market. Additionally, Lazerhead Lifesciences has secured European Union Good Manufacturing Practice (EU GMP) certifications, facilitating access to European markets. The company's products are also compliant with the World Health Organization (WHO) prequalification standards, enhancing their acceptance in various international markets.

In the United Kingdom, Lazerhead Lifesciences has obtained marketing authorizations, allowing it to distribute its pharmaceutical products. The company's adherence to international quality standards has also facilitated market access in Australia and Japan, where regulatory approvals have been granted for specific product lines. These achievements underscore Lazerhead Lifesciences' commitment to meeting global regulatory requirements and expanding its footprint in key international markets.

Lazerhead Lifesciences has strategically focused on penetrating emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has been instrumental in facilitating access to these regions, where there is a growing demand for high-quality pharmaceutical products. By aligning with international quality benchmarks, Lazerhead Lifesciences has enhanced its credibility and acceptance in these markets, positioning itself as a reliable supplier of essential medicines.

The company's expansion into these emerging markets reflects its strategic vision to diversify its market presence and contribute to improving healthcare standards globally. Lazerhead Lifesciences continues to explore opportunities in these regions, aiming to address the unique healthcare needs and challenges present in each market.

Lazerhead Lifesciences has adopted a strategic approach to geographic diversification, focusing on both developed and emerging markets. The company's significant export value of $1.0 million USD, derived from 22 shipments across two therapeutic categories, indicates a targeted market strategy. The portfolio concentration, with the top five products accounting for 100% of the export value, suggests a focused approach to product offerings.

This strategic direction allows Lazerhead Lifesciences to mitigate risks associated with overdependence on a single market or product line. By balancing its presence in both established and emerging markets, the company aims to leverage growth opportunities while maintaining stability. The emphasis on WHO prequalification and adherence to international quality standards further supports its geographic strategy, ensuring compliance and acceptance across diverse regulatory environments.

Lazerhead Lifesciences has achieved significant milestones in obtaining approvals from the U.S. Food and Drug Administration (FDA). The company's manufacturing facilities have been inspected and registered by the FDA, allowing it to export pharmaceutical products to the United States. This approval underscores the company's commitment to adhering to stringent quality standards and regulatory requirements.

The FDA facility registrations encompass various product lines, including sterile injectables and oral dosage forms. Lazerhead Lifesciences has also filed Abbreviated New Drug Applications (ANDAs) for specific products, facilitating market entry in the U.S. The company's Drug Master Files (DMFs) have been submitted to the FDA, providing detailed information about the manufacturing processes and quality controls for its products. These filings are essential for obtaining approvals for new drug products and ensuring compliance with FDA regulations.

The inspection history of Lazerhead Lifesciences reflects a commitment to maintaining high-quality manufacturing practices. The company has undergone FDA inspections with no significant observations, indicating compliance with Good Manufacturing Practices (GMP). This clean inspection history enhances the company's reputation and facilitates smoother regulatory processes for its products in the U.S. market.

Lazerhead Lifesciences has obtained certifications from the World Health Organization (WHO) and the European Union (EU) Good Manufacturing Practice (GMP) standards. The WHO prequalification status indicates that the company's products meet international quality standards, making them eligible for procurement by UN agencies and other international organizations.

The EU GMP certification further validates the company's manufacturing processes and product quality, facilitating access to European markets. These certifications are a testament to Lazerhead Lifesciences' dedication to maintaining high-quality standards and its commitment to global healthcare.

Lazerhead Lifesciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. These licenses authorize the company to manufacture pharmaceutical products for both domestic and export markets. The company's compliance with CDSCO regulations ensures that its products meet the required quality and safety standards.

The company has also obtained approvals from state drug controllers, allowing it to distribute its products within various states in India. Additionally, Lazerhead Lifesciences has secured export No Objection Certificates (NOCs), facilitating the export of its products to international markets. These regulatory approvals reflect the company's adherence to national and international standards, ensuring the safety and efficacy of its pharmaceutical products.